4D Molecular Therapeutics FDMT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $88.24M+383,561% | $85.21M+230,195% | $120K+233% | $33K-99.8% | $23K-99.9% | ||
| $219.98M+42.7% | $195.7M+38.5% | $181.18M+45.8% | $170.22M+53.6% | $154.13M+50.3% | ||
| $47.81M-2.9% | $49.06M+5.3% | $49.32M+11.7% | $50.14M+23.5% | $49.22M+26.8% | ||
| $267.79M+31.7% | $244.76M+30.3% | $230.5M+36.9% | $220.36M+45.5% | $203.35M+43.9% | ||
| $267.79M+31.7% | $244.76M+30.3% | $230.5M+36.9% | $220.36M+45.5% | $203.35M+43.9% | ||
| -$194.26M+4.5% | -$174.26M+7.2% | -$230.38M-36.8% | -$220.33M-67.9% | -$203.33M-68.2% | ||
| -220.1%+883,806pp | -204.5%+507,474pp | -191,982.5%+275,729pp | -667,654.5%-667,006pp | -884,026.1%-883,436pp | ||
| $18.76M-30.2% | $19.48M-28.0% | $21.24M-14.9% | $24.2M+12.3% | $26.89M+62.8% | ||
| $18.65M-30.6% | $19.44M-27.9% | $21.2M-14.8% | $24.18M+13.4% | $26.89M+64.5% | ||
| —— | —— | -$209.18M-45.8% | -$196.14M-78.5% | -$176.44M-68.8% | ||
| —— | —— | -$3.75-31.6% | -$3.53-53.5% | -$3.18-30.3% | ||
| —— | —— | -$3.75-31.6% | -$3.53-53.5% | -$3.18-30.3% | ||
| 238M+7.9% | 225.7M+5.5% | 221.7M+11.3% | 221.2M+18.9% | 220.5M+30.5% | ||
| 238M+7.9% | 225.7M+5.5% | 221.7M+11.3% | 221.2M+18.9% | 220.5M+30.5% | ||
| -$108K— | -$37K+51.9% | -$36K+46.3% | -$16K+92.9% | $0+100% | ||
| $219.98M+42.7% | $195.7M+38.5% | $181.18M+45.8% | $170.22M+53.6% | $154.13M+50.3% | ||
| $88.24M+383,561% | $85.21M+230,195% | $120K+233% | $33K-99.8% | $23K-99.9% | ||
| -$194.26M+4.5% | -$174.26M+7.2% | -$230.38M-36.8% | -$220.33M-67.9% | -$203.33M-68.2% | ||
| -$189.35M+4.8% | -$169.57M+7.4% | -$225.81M-37.9% | -$215.82M-70.3% | -$198.8M-70.6% | ||
| -$189.35M+4.8% | -$169.57M+7.4% | -$225.81M-37.9% | -$215.82M-70.3% | -$198.8M-70.6% | ||
| -214.6%+864,112pp | -199%+494,904pp | -188,170.8%+266,599pp | -654,009.1%-653,383pp | -864,326.1%-863,757pp | ||
| -$194.26M+4.5% | -$174.26M+7.2% | -$230.38M-36.8% | -$220.33M-67.9% | -$203.33M-68.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is 4D Molecular Therapeutics's revenue?
- 4D Molecular Therapeutics (FDMT) generated $88.2M in revenue over the trailing twelve months, up 383560.9% year over year.
- Is 4D Molecular Therapeutics profitable?
- 4D Molecular Therapeutics is not currently profitable: it reported a net loss of $228.3M over the trailing twelve months, a -174314.2% net margin.
- What is 4D Molecular Therapeutics's earnings per share?
- 4D Molecular Therapeutics's diluted EPS over the trailing twelve months is $-3.86.
- Where does 4D Molecular Therapeutics's income statement data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
